Startups
Edit
Surveillance, Epidemiology, and End Results Program
https://seer.cancer.gov/Last activity: 21.09.2026
Active
Categories: Data
An authoritative source for cancer statistics in the US. We collect incidence, prevalence and survival data and publish reports on these and cancer mortality. For those interested in cancer statistics and surveillance methods.
Website visits
762.7K /mo.
Mentions
172
Mentions in press and media 172
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 14, 2026 | Update on SERENA-4 Phase III trial | Update on SERENA-4 Phase III trial Mon, Sep 14, 2026 08:00 CET Report this content This announcement contains inside information 14 September 2026 Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-... |
| Sep 1, 2026 | Enhertu approved in EU for 1L HER2-positive mBC | Enhertu approved in EU for 1L HER2-positive mBC Tue, Sep 01, 2026 08:30 CET Report this content 01 September 2026 Enhertuplus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients wi... |
| Aug 26, 2026 | HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCAR™ T-Cell | KEY POINTS First patient safely dosed in Phase 1 KOALA trial evaluating KMCAR™ T-cell therapy in patients with relapsed/refractory kappa-restricted multiple myeloma Patient was monitored after initial dose to assess response and side-effect... |
| Jul 31, 2026 | Low Arginine Silences Immune Alert System in Cancer and Infection, Cell Study Finds | By Donald C. Case Published: Jul 31 2026, 3:06 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jul 31, 2026 | Datroway approved in EU for TNBC | Datroway approved in EU for TNBC Fri, Jul 31, 2026 08:48 CET Report this content 31 July 2026 Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic T... |
| Jul 23, 2026 | Etcamah approved in the EU for ER+ breast cancer | Etcamah approved in the EU for ER+ breast cancer Thu, Jul 23, 2026 08:25 CET Report this content 23 July 2026 Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer A... |
| Jul 21, 2026 | Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer | • First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). • LUTEON is the first Phase 3 study of a CAIX[2]-targeted radiopharmaceutical therapy in ccRCC MELBOURNE... |
| Jul 19, 2026 | Skinmetal targets the gender gap in sunscreen use | Men are diagnosed with melanoma at a higher rate than women and die from it more often. According to the National Cancer Institute figures, there are 28.3 new cases and 2.9 deaths per 100,000 men, compared to 17.9 new cases and 1.3 deaths p... |
| Jul 10, 2026 | FDA to Rule July 17 on Gedatolisib, First Targeted Therapy for PIK3CA Wild-Type Breast Cancer | By John Bright Published: Jul 10 2026, 4:19 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| Jun 29, 2026 | Datroway recommended for approval in EU for TNBC | Datroway recommended for approval in EU for TNBC Mon, Jun 29, 2026 08:00 CET Report this content 29 June 2026 Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast canc... |
| May 27, 2026 | US FDA decision date on camizestrant extended | US FDA decision date on camizestrant extended Wed, May 27, 2026 08:00 CET Report this content 27 May 2026 US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data The US Food and Drug Administrat... |
| May 26, 2026 | Datroway approved in US for 1L triple-negative BC | Datroway approved in US for 1L triple-negative BC Tue, May 26, 2026 08:00 CET Report this content 26 May 2026 Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic tri... |
| May 26, 2026 | Camizestrant recommended for breast cancer in EU | Camizestrant recommended for breast cancer in EU Tue, May 26, 2026 08:00 CET Report this content 26 May 2026 Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive br... |
| May 18, 2026 | Enhertu approved in two HER2+ early BC settings | Enhertu approved in two HER2+ early BC settings Mon, May 18, 2026 08:05 CET Report this content 18 May 2026 Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer Approved for use before surge... |
| May 11, 2026 | CDMRP Drives Discovery of New Treatments for Brain Cancers | The Congressionally Directed Medical Research Programs support research into new treatments for brain cancers affecting Service Members and their Families. Brain and central nervous system tumors are among the most common cancers for adoles... |
| May 1, 2026 | FDA ODAC vote on camizestrant in breast cancer | FDA ODAC vote on camizestrant in breast cancer Fri, May 01, 2026 08:05 CET Report this content 01 May 2026 Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer T... |
| Mar 26, 2026 | SignaBlok to Present Novel Approach to Preventing Pancreatic Cancer Recurrence at the 2026 AACR Annual Meeting | SignaBlok Logo Timely resolution of inflammation induced by standard-of-care cancer treatments can be a common approach to prevent cancer recurrence in multiple cancer types We are glad to report the previously unrecognized phenomenon of cr... |
| Feb 12, 2026 | FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer | FDA News Release Device Delivers Non-invasive Therapy and Supports Care at Home For Immediate Release: February 12, 2026 The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with ... |
| Dec 22, 2025 | Enhertu granted BTD for post-neoadjuvant early BC | Enhertu granted BTD for post-neoadjuvant early BC Mon, Dec 22, 2025 08:30 CET Report this content 22 December 2025 Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early ... |
| Dec 16, 2025 | Enhertu approved in US for 1L HER2+ metastatic BC | Enhertu approved in US for 1L HER2+ metastatic BC Tue, Dec 16, 2025 08:00 CET Report this content 16 December 2025 Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER... |
| Oct 28, 2025 | ‘Cancer doesn’t care’: Citizen lobbyists unite to push past Washington’s ugly politics | By Noam N. Levey, KFF Health News Mary Catherine Johnson is a retired small-business owner from outside Rochester, New York. She voted for Donald Trump three times. Related Articles Trump ramps up involvement in this year’s elections in pos... |
| Oct 6, 2025 | Datroway improved OS and PFS in TROPION-Breast02 | Datroway improved OS and PFS in TROPION-Breast02 Mon, Oct 06, 2025 08:30 CET Report this content 6 October 2025 Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy fo... |
| Oct 5, 2025 | To treat prostate cancer, there are more options than ever | An estimated one in eight men will be diagnosed with prostate cancer in their lifetime, often after 65. And as terrifying as that number is, a diagnosis isn’t always quite what it seems. Today, the vast majority of patients will survive the... |
| Apr 22, 2025 | Enhertu combination improved PFS in 1L HER2+ mBC | Enhertu combination improved PFS in 1L HER2+ mBC Tue, Apr 22, 2025 08:00 CET Report this content This announcement contains inside information 22 April 2025 Enhertu plus pertuzumab demonstrated highly statistically significant and clinicall... |
| Apr 21, 2025 | Report finds steady decline in cancer death rates | Overall cancer death rates declined steadily among both men and women from 2018 through 2022, according to the National Institutes of Health's latest annual report. Cancer death rates decreased an average of 1.7% per year for men and 1.3% p... |
| Apr 7, 2025 | Uncovering Mechanisms Driving Estrogen Receptor-Negative Breast Cancer | Susan Clare, ‘90 MD, ‘88 PhD, research associate professor of Surgery in the Division of Breast Surgery, was co-senior author of the study published in Science Advances. Northwestern Medicine investigators have discovered previously unknown... |
| Apr 4, 2025 | Enhertu approved in EU in post-ET breast cancer | Enhertu approved in EU in post-ET breast cancer Fri, Apr 04, 2025 08:00 CET Report this content 04 April 2025 Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic brea... |
| Mar 1, 2025 | Camizestrant: A New Dawn in HR+ Breast Cancer Treatment | In the ever-evolving landscape of breast cancer treatment, a new contender has emerged: camizestrant. This investigational drug is making waves in the medical community, particularly for patients battling hormone receptor-positive (HR+) bre... |
| Feb 26, 2025 | Camizestrant improved PFS in 1L HR+ breast cancer | Camizestrant improved PFS in 1L HR+ breast cancer Wed, Feb 26, 2025 08:00 CET Report this content This announcement contains inside information 26 February 2025 Camizestrant demonstrated highly statistically significant and clinically meani... |
| Feb 13, 2025 | OnCusp Therapeutics: A New Hope for Ovarian Cancer Patients | In the realm of cancer treatment, hope often feels like a flickering candle in a storm. Yet, OnCusp Therapeutics is igniting that flame with its recent FDA Fast Track Designation for CUSP06, a promising therapy for platinum-resistant ovaria... |
| Feb 12, 2025 | OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer | PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, tod... |
| Jan 28, 2025 | Enhertu approved in US for breast cancer post ET | Enhertu approved in US for breast cancer post ET Tue, Jan 28, 2025 08:00 CET Report this content 28 January 2025 Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cance... |
| Jan 20, 2025 | Dato-DXd approved in US for HR+ breast cancer | Dato-DXd approved in US for HR+ breast cancer Mon, Jan 20, 2025 08:00 CET Report this content 20 January 2025 Datroway (datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative br... |
| Dec 13, 2024 | The Heart of the Matter: Plant Proteins and Their Role in Cardiovascular Health | In a world where food choices shape our health and the environment, a recent Harvard study sheds light on the power of plant proteins. It’s a call to action, urging us to rethink our plates. The findings are clear: more plants, less meat. T... |
| Dec 12, 2024 | Navigating the ups and downs of the lymphoma journey | Listen to this article Navigating the ups and downs of the lymphoma journey 7 min New: You can now listen to articles. This audio is generated by an AI tool. A lymphoma diagnosis often leaves patients with deep uncertainty. In Singapore, th... |
| Nov 28, 2024 | The Double-Edged Sword of Innovation in Medicine | In the world of medicine, innovation is a double-edged sword. On one side, it brings hope and healing. On the other, it can lead to unforeseen consequences. Recent developments in the pharmaceutical landscape highlight this dichotomy vividl... |
| Nov 27, 2024 | Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC | CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Products Administration (NM... |
| Oct 4, 2024 | Onco360® Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra® (tislelizumab-jsgr) | LOUISVILLE, Ky., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Beigene for Tevimbra® (tislelizumab), approved for the treatment of adult patients ... |
| Sep 23, 2024 | Final OS results reported for TROPION-Breast01 | Final OS results reported for TROPION-Breast01 Mon, Sep 23, 2024 08:00 CET Report this content 23 September 2024 Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative br... |
| Sep 23, 2024 | Health | How AI can help researchers make esophageal cancer less deadly | This is why only about 20% of Americans with esophageal cancer are still alive five years after their diagnosis. To improve on that figure, doctors say they don’t necessarily need better medicines. What they need are better ways to find the... |
| Sep 11, 2024 | Building Bridges in Cancer Care: The Push for Diversity and Inclusion | In the heart of Washington, D.C., a significant conversation unfolded at the National Comprehensive Cancer Network (NCCN) Policy Summit. The focus? Diversity, equity, and inclusion (DEI) in oncology. This summit was not just another meeting... |
| Sep 10, 2024 | Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw) | Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT®, a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO, Sept. 10, 2024 /PRNewswire/ -- J... |
| Sep 9, 2024 | Health | Breast cancer rises among Asian American and Pacific Islander women | The rate of new breast cancer cases among Asian American and Pacific Islander women under 50 grew by about 52% from 2000 through 2021. Rates for AAPI women 50 to 64 grew 33% and rates for AAPI women 65 and older grew by 43% during that peri... |
| Sep 4, 2024 | Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma | SAN FRANCISCO and SUZHOU, China, Sept. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| Aug 8, 2024 | Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant | Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant Sarclisa (isatuximab) in combination with standard-of-care lenalidomide, bo... |
| Jul 5, 2024 | Health | 10 sunscreen myths you can’t afford to fall for | Sunscreens can protect you from these malignancies in one of two ways. Chemical sunscreens contain ingredients such as avobenzone that absorb UV rays. Mineral sunscreens rely on zinc oxide or titanium dioxide to block or reflect the rays. E... |
| Jul 4, 2024 | HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of a... |
| Jul 1, 2024 | Lynparza & Imfinzi positive CHMP in endometrial | Lynparza & Imfinzi positive CHMP in endometrial Mon, Jul 01, 2024 08:00 CET Report this content 1 July 2024 Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advance... |
| Jun 18, 2024 | Update on CAPItello-290 Phase III trial | Update on CAPItello-290 Phase III trial Tue, Jun 18, 2024 08:00 CET Report this content 18 June 2024 Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer The CAPIte... |
| Jun 12, 2024 | Knowledge Graphs: Context, Compliance, and Connections | “Graph is leaving a larger and larger footprint. And that is good,” said Thomas Frisendal in Knowledge Graphs and Data Modeling. Gartner named knowledge graphs as part of an emerging trend toward digital ecosystems, showing relationships am... |
| Jun 7, 2024 | HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in... |
| May 27, 2024 | Telix Submits NDA for New Prostate Cancer Imaging Agent | MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for... |
| May 3, 2024 | New Guidance Recommends Breast Cancer Screening Every 2 Years for Women 40 and Older | Women ages 40 to 74 should be screened for breast cancer every two years, according to an updated recommendation released by the U.S. Preventive Services Task Force (USPSTF) on Tuesday, April 30. Previously, the USPSTF recommended that scre... |
| Apr 29, 2024 | Truqap recommended for EU breast cancer approval | Truqap recommended for EU breast cancer approval Mon, Apr 29, 2024 08:05 CET Report this content 29 April 2024 Truqap plusFaslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer Recommendatio... |
| Apr 2, 2024 | FDA accepts Dato-DXd BLA for breast cancer | FDA accepts Dato-DXd BLA for breast cancer Tue, Apr 02, 2024 08:00 CET Report this content 2 April 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER... |
| Mar 4, 2024 | EMA validates Dato-DXd MAAs for NSQ NSCLC and BC | EMA validates Dato-DXd MAAs for NSQ NSCLC and BC Mon, Mar 04, 2024 08:00 CET Report this content 4 March 2024 Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or H... |
| Feb 27, 2024 | Freenome scores $254M to advance its cancer-detection blood tests | The San Francisco company readies to reveal its first clinical study results in the near term When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un... |
| Feb 19, 2024 | FDA accepts Dato-DXd BLA for nonsquamous NSCLC | FDA accepts Dato-DXd BLA for nonsquamous NSCLC Mon, Feb 19, 2024 08:05 CET Report this content 19 February 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamou... |
| Jan 26, 2024 | BioPhenoMA Co., Ltd. Aiming to develop new biomarkers for urothelial cancer BioPhenoMA signs joint research agreement with Tokyo Medical University | BioPhenoMA Co., Ltd. Aiming to develop new biomarkers for urothelial cancer BioPhenoMA signs joint research agreement with Tokyo Medical University ~Aiming to alleviate patient pain as much as possible~ …… BioPhenoMA Co., Ltd. (Shinjuku-ku,... |
| Jan 26, 2024 | BioPhenoMA Co., Ltd. Aiming to develop new biomarkers for urothelial cancer BioPhenoMA signs joint research agreement with Tokyo Medical University | |
| Nov 17, 2023 | Truqap approved in US for HR+ breast cancer | Truqap approved in US for HR+ breast cancer Fri, Nov 17, 2023 08:00 CET Report this content 17 November 2023 Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer First-in-class AKT inhi... |
| Sep 22, 2023 | Dato-DXd improved PFS in breast cancer | Dato-DXd improved PFS in breast cancer Fri, Sep 22, 2023 08:00 CET Report this content This announcement contains inside information 22 September 2023 Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful p... |
| Aug 17, 2023 | Medicare beneficiaries deserve access to genetic counselors | Precision medicine driven by genetic health care is knocking on the door. It offers hope that, sooner than later, we can address health problems like Alzheimer’s disease, cancer, and heart disease that affect the lives of so many Americans.... |
| Jun 15, 2023 | FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer | SAN FRANCISCO, June 15, 2023 /PRNewswire/ -- Biostar Pharma, Inc. (hereinafter referred to as "Biostar"), the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusin... |
| Apr 5, 2023 | Lynparza + Imfinzi met endpoint in ovarian cancer | Lynparza + Imfinzi met endpoint in ovarian cancer Wed, Apr 05, 2023 08:00 CET Report this content 5 April 2023 07:00 BST Lynparza and Imfinzi combination improved progression-free survival in newly diagnosed patients with advanced ovarian c... |
| Mar 19, 2023 | In Cancer, Patient-Empowering AI Begins To Change Care, Relationships | Researchers who applied artificial intelligence applied to the doctor's notes were able to predict ... [+] survival for cancer patients with 80 to 90 percent accuracy, possibly opening the way for an app allowing patients to do this themsel... |
| Mar 14, 2023 | Медицинские датасеты для машинного обучения: цели, типы и способы применения | Международная система здравоохранения ежедневно генерирует множество медицинских данных, которые (по крайней мере, теоретически) можно использовать для машинного обучения. В любой отрасли данные считаются ценным ресурсом, который помогает к... |
| Mar 2, 2023 | Parents Up in Arms Over California Assembly Bill That Would Require all 8th through 12th Grade Teens to Receive Gardasil Vaccine | The science is not settled on the Gardasil HPV vaccine. Peer reviewed publications have demonstrated that Merck has oversold the efficacy of its HPV vaccine and downplayed the risks, to the point that hundreds of young women and men are sui... |
| Feb 24, 2023 | Breast cancer: What you should know about the most common cancer diagnosis | There are many myths attached to breast cancer, the most common cancer in the world. They range from beliefs that wearing a bra or using anti-perspirant causes breast cancer to claims that breast cancer only affects older women, or that men... |
| Jan 31, 2023 | A Peloton instructor was diagnosed with breast cancer at age 35. Here's how common the disease is at every age. | A mammogram. Bizuayehu Tesfaye / AP Images Breast cancer is one of the most common cancers for women. The risk of getting the disease generally increases with age, but young people can get it too. A 35-year-old Peloton instructor recently s... |
| Jan 24, 2023 | Uterine Cancer Diagnostics Market Set to Reach Valuation of USD 19,386.15 Million by 2030, Size, Share, Demand, Future Growth, Challenges and Competitive Analysis | SYDNEY, Jan. 24, 2023 /PRNewswire/ -- Data Bridge Market Research has recently published a Report, titled, "Uterine Cancer Diagnostics Market" The report offers an extensive analysis of key growth strategies, drivers, opportunitie... |
| Jan 20, 2023 | DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression | PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 20, 2023 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targ... |
| Jan 20, 2023 | BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS | TORONTO, Canada and BEIJING, Jan. 20, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform... |
| Dec 19, 2022 | Enhertu approved in EU for gastric cancer | Enhertu approved in EU for gastric cancer Mon, Dec 19, 2022 08:15 CET Report this content 19 December 2022 07:15 GMT Enhertu approved in the EU for patients with previously treated HER2-positive advanced gastric cancer First HER2-directed m... |
| Dec 8, 2022 | Capivasertib PFS in HR-positive breast cancer | Capivasertib PFS in HR-positive breast cancer Thu, Dec 08, 2022 14:30 CET Report this content 8 December 2022 13:30 GMT Capivasertib plus Faslodex reduced the risk of disease progression or death by 40% versus Faslodex in advanced HR-positi... |
| Dec 5, 2022 | Review of the use of the bioimpedance diagnostic device for melanoma and dysplastic nevi with a high risk of malignancy | Early diagnosis of skin cancer at the price of a smart watch Early diagnosis of skin cancer at the price of a smart watch Dr. Alessia Niddeger, oncodermatilogy, Switzerland, Dr. Jessica Perez Ares Ruz, oncodermatology, cosmetology, Mexico, ... |
| Nov 14, 2022 | Enhertu recommended for EU approval in gastric | Enhertu recommended for EU approval in gastric Mon, Nov 14, 2022 08:10 CET Report this content 14 November 2022 07:10 GMT Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive advanced gastric... |
| Nov 1, 2022 | Single Blood Test Cancer Screening? Doctors Introduce Tech that Can Detect Multiple Cancers At Once | John Lopez, Tech Times 01 November 2022, 09:11 am According to the National Cancer Institute, approximately 1.9 million people will be diagnosed with cancer in the United States in 2022, with an estimated 609,360 dying as a result of cancer... |
| Oct 14, 2022 | Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer | Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and 108,000 prostate cancer-related deaths occ... |
| Jun 9, 2022 | Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong | - Highly sensitive ColoClear test offers convenient screening method that can be completed with simple stool sample at-home, providing an easy alternative to Colonoscopy - Test sensitivity of 96% in colorectal cancer and 64% in advanced ade... |
| Apr 29, 2022 | Fact Sheet: Celebrating Asian American, Native Hawaiian, and Pacific Islander Heritage Month 2022 | The Biden-Harris Administration is committed to advancing health equity and improving health outcomes of Asian American, Native Hawaiian, and Pacific Islander communities. An estimated 24 million Asian Americans and 1.6 million Native Hawai... |
| Apr 26, 2022 | Родинки — это плохо? Разбираемся с эстетикой и раком кожи (не всё так страшно) | Родинки уже который год ставят рекорды по мифам и страшилкам. Одно только клиническое исследование «Даже однократное посещение солярия повышает риск развития рака кожи в два раза!» чего стоит! Пруф. Но бояться их не надо. Их надо отслеживат... |
| Apr 22, 2022 | CStone Announces Results From Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine | Results from the trial present a significant advancement for patients dealing with previously untreated IDH1-mutated AML Global Phase 3 trial of TIBSOVO (ivosidenib tablets) met its primary endpoint of event-free survival and all key second... |
| Apr 15, 2022 | Phones don’t cause brain tumors, experts say | A growing body of evidence shows that mobile phones don’t cause brain cancer. Contents Reassuring ResultsBrain Cancer Remains A Concern The use of mobile phones does not increase brain tumor incidence, according to a new study. The research... |
| Apr 5, 2022 | EIT Health-supported Optellum attains CE mark | EIT Health-supported start-up, Optellum, headquartered in Oxford, UK, has attained a CE mark for its innovative solution which supports the precision diagnosis of lung cancer in its earliest stages. Their technology, the Virtual Nodule Clin... |
| Mar 19, 2022 | I learned a 5-step routine to check my body for hidden, risky moles — and why you shouldn't do it more than once a month | Health I learned a 5-step routine to check my body for hidden, risky moles — and why you shouldn't do it more than once a month Hilary Brueck 2022-03-19T12:00:00Z Share icon An curved arrow pointing right. Share Facebook Icon The letter F. ... |
| Feb 15, 2022 | Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma | DGAP-News: Heidelberg Pharma AG / Key word(s): Study Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma 15.02.2022 / 07:10 The issuer is solely responsible for the content o... |
| Jan 19, 2022 | HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that updated analysis of the ongoing international Phase I/Ib trial of fruqui... |
| Jan 19, 2022 | HUTCHMED China : Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium - Form 6-K | HUTCHMED Highlights Fruquintinib Clinical Data to be Presented at the 2022 ASCO Gastrointestinal Cancers Symposium Hong Kong, Shanghai & Florham Park, NJ - Wednesday, January 19, 2022: HUTCHMED (China) Limited ("HUTCHMED") (... |
| Dec 13, 2021 | Phase 3 Data Demonstrate TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia | TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvements in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objecti... |
| Dec 6, 2021 | HUTCHMED China : Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer - Form 6-K | HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer - Recruitment of 687 patients globally completed in fifteen months, ahead of schedule - - FRESCO-2 primary objective... |
| Dec 6, 2021 | HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer | — Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study1, and to support global registrations — HONG ... |
| Dec 4, 2021 | Marjorie Taylor Greene Compares Covid-19 To Cancer, Here’s The Twittersphere Response | Rep. Marjorie Taylor Greene (R-GA) tweeted that “every single year more than 600,000 people in the ... [+] US die from cancer” and “not a single school has closed.” (Photo by Win McNamee/Getty Images) Getty Images |
| Nov 12, 2021 | Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients | Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain blood cancersLCD supports the expansion o... |
| Nov 9, 2021 | IASO Biotheraputics Completes Enrollment of First Patient in CT120's Phase I/II Registrational Clinical Trial | SAN JOSE, Calif. and SHANGHAI and NANJING, China, Nov. 9, 2021 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines, today ann... |
| Nov 5, 2021 | New Data at ASH 2021 Reinforces the Strength of Servier's Hematology Portfolio | First Phase 3 results from the AGILE trial in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation show improved event-free survival and various secondary outcomes, including complete remission, overall survival and ob... |
| Oct 18, 2021 | AB Science : granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML) | PRESS RELEASE AB SCIENCE GRANTED AUTHORIZATION FROM THE FRENCH HEALTH AUTHORITY (ANSM) TO INITIATE A STUDY OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) SECOND AUTHORIZATION FOR PHASE I/II TRIAL AB18001 PERMITS PATIENT RECRUITM... |
| Sep 30, 2021 | Aspira Women Health : Black Women's Health Imperative Lead Congressional Briefing | AUSTIN, Texas, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc (“Aspira”) (Nasdaq: AWH) together with the Black Women’s Health Imperative participated in a Congressional Briefing on September 27, 2021 to discuss the gaps in ova... |
| Sep 22, 2021 | AB Science : receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML) | PRESS RELEASE AB SCIENCE RECEIVES HEALTH CANADA APPROVAL LETTER TO COMMENCE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW GENERATION SYNTHETIC MICROTUBULE DESTABILIZER WITH THE ABILITY TO OVERCO... |
Show more
Reviews 0
FAQ about Surveillance, Epidemiology, and End Results Program
What has the press written about Surveillance, Epidemiology, and End Results Program?
Parsers VC has collected 172 articles mentioning Surveillance, Epidemiology, and End Results Program, among them “Update on SERENA-4 Phase III trial” (Sep 14, 2026) and “Enhertu approved in EU for 1L HER2-positive mBC” (Sep 1, 2026).
Is Surveillance, Epidemiology, and End Results Program still active?
Yes, Surveillance, Epidemiology, and End Results Program is active; its latest activity on Parsers VC dates from Sep 21, 2026.